Timothy Yap

Professor The University of Texas MD Anderson Cancer Center

Seminars

Wednesday 28th January 2026
Exploring WRN Inhibition in MSI Tumors to Expand Synthetic Lethality Strategies Beyond PARP
11:30 am
  • See how the MD Anderson Cancer Center are advancing first-in-human trial data for WRN inhibitors in MSI solid tumors
  • Interpreting translational relevance and biomarker integration
  • Positioning WRN as a synthetic lethality target beyond PARP
Vice President & Head of Clinical Development & Therapeutics Discovery Medical, Institute For Applied Cancer Science at MD Anderson Cancer Center, speaker for DDR Inhibitors Summit